HANNAH FOLDS: Open Payments
NPI 1922412022 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,092 in 53 payments from 17 companies in 2025. Trend: 2023 $856 · 2024 $1,134 · 2025 $1,092
Food & beverage: $1,092
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 5 | $149 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $141 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $140 |
| Janssen Biotech, Inc. | 8 | $132 |
| Gilead Sciences, Inc. | 4 | $98 |
| Ipsen Biopharmaceuticals, Inc | 4 | $77 |
| ABBVIE INC. | 3 | $66 |
| GENZYME CORPORATION | 2 | $47 |
| Lilly USA, LLC | 2 | $47 |
| Organon LLC | 2 | $37 |
Products named: REZDIFFRA, XIFAXAN, TREMFYA, ENTYVIO, IQIRVO, DUPIXENT, OMVOH, HADLIMA.
Industry payments across GA — which companies pay providers there.
